

pared to the other two antigens (Hongliang *et al.*, 2010). The different reactivities observed among these three proteins might be due to the differences in their immun accessibility; for example, the immune system could easily produce antibodies against the surface-exposed components of *C. pneumoniae*, while an intracellular antigen may induce little or no response.

Several clones were frequently recognized by antibodies of different isotypes in the patients' sera: Cpj0068, Cpj0147, Cpj0186, Cpj0677, Cpj0726, and Cpj0727 by IgA antibody; and Cpj0147, Cpj0186, Cpj0308, Cpj0677, Cpj0706, Cpj0726, and Cpj0727 by IgG antibody (Fig. 3a). The proteins encoded by these ORFs could be candidates for the antigens when developing more sensitive ELISA tests. Cpj0147, Cpj0186, Cpj0308, and Cpj0677, which have no orthologs in the *C. trachomatis* genome, could be viable candidates for *C. pneumoniae*-specific antigens for the immunological detection of *C. pneumoniae* and diagnostic assays for patients with potential *C. pneumoniae* infections. Cpj0147 and Cpj0308 may be particularly useful because they were reported to be localized in the *C. pneumoniae* inclusion membrane (Hongliang *et al.*, 2010). Among the 39 ORFs recognized by at least one serum sample (Fig. 3b), Cpj0159, Cpj0178, Cpj0268, Cpj0472, Cpj0678, Cpj1056, and Cpj1070 have no ortholog in the *C. trachomatis* genome. These clones were detected by several patient serum samples, indicating that these clones can induce antigenic antibody responses in the host. Protein encoded by just one of these ORFs may not induce an antibody response sufficient for diagnosis, but combinations of these ORFs may be useful for the development of immunoassays.

In a previous study, inactivated whole chlamydial organism-based vaccines failed to induce protective immunity in humans, and live chlamydial infection in animal models always induces better protective immunity than immunization with inactivated organisms (Grayston *et al.*, 1962). These results have generated a hypothesis that some infection-dependent antigens could induce protective responses. It is, therefore, important to identify infection-dependent antigens, which are expressed during chlamydial infection in humans, and to determine their roles in protective immunity. Many chlamydial antigens that elicit immune responses in humans have been found in this study, and our data provide valuable information toward the development of new serological diagnostics for *C. pneumoniae* infection. Further research is required to validate the use of these specific and highly immunogenic antigens for development of an accurate and reliable serodiagnostic tool for *C. pneumoniae*. In addition, such antigens could potentially lead to the development of a vaccine that could stimulate a protective immune response in humans.

Acknowledgements

This work was supported in part by Grant-in-Aid for scientific research from the Ministry of Education, Science and Culture of Japan, and Research Project Grants from Kawasaki Medical School.

Statement

Informed consent was obtained from the parents of all the patients and the control subjects, in accordance with institutional review board guidelines. The ethics committees of the hospitals approved the study.

References

- Bunk S, Susnea I, Rupp J, Summersgill JT, Maass M, Stegmann W, Schratzenholz A, Wendel A, Przybylski M & Hermann C (2008) Immunoproteomic identification and serological responses to novel *Chlamydia pneumoniae* antigens that are associated with persistent *C. pneumoniae* infections. *J Immunol* **180**: 5490–5498.
- Grayston JT (2000) Background and current knowledge of *Chlamydia pneumoniae* and atherosclerosis. *J Infect Dis* **181**: S402–S410. Review
- Grayston JT, Woolrodge RL & Wang S (1962) Trachoma vaccine studies on Taiwan. *Ann NY Acad Sci* **98**: 352–367.
- Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH & Wang SP (1990) A new respiratory tract pathogen: *Chlamydia pneumoniae* strain TWAR. *J Infect Dis* **161**: 618–625.
- Hongliang C, Zhou Z, Zhan H, Yanhua Z, Zhongyu L, Yingbiao L, Guozhi D & Yimou W (2010) Serodiagnosis of *Chlamydia pneumoniae* infection using three inclusion membrane proteins. *J Clin Lab Anal* **24**: 55–61.
- Iijima Y, Miyashita N, Kishimoto T, Kanamoto Y, Soejima R & Matsumoto A (1994) Characterization of *Chlamydia pneumoniae* species-specific proteins immunodominant in humans. *J Clin Microbiol* **32**: 583–588.
- Klein M, Kötz A, Bernardo K & Krönke M (2003) Detection of *Chlamydia pneumoniae*-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein. *J Clin Microbiol* **41**: 1957–1962.
- Kuo CC, Jackson LA, Campbell LA & Grayston JT (1995) *Chlamydia pneumoniae* (TWAR). *Clin Microbiol Rev* **8**: 451–461. Review.
- Miura K, Inouye S, Sakai K *et al.* (2001) Cloning and characterization of adenylate kinase from *Chlamydia pneumoniae*. *J Biol Chem* **276**: 13490–13498.
- Miyashita N, Ouchi K, Kawasaki K, Komura H, Kawai Y, Tsumura N, Bannai H, Iwata S & Oka M (2008) Comparison of serological tests for detection of immunoglobulin M antibodies to *Chlamydia pneumoniae*. *Respirology* **13**: 427–431.

- Mygind P, Christiansen G, Persson K & Birkelund S (1998) Analysis of the humoral immune response to *Chlamydia* outer membrane protein 2. *Clin Diagn Lab Immunol* **5**: 313–318.
- Ozanne G & Lefebvre J (1992) Specificity of the microimmunofluorescence assay for the serodiagnosis of *Chlamydia pneumoniae* infections. *Can J Microbiol* **38**: 1185–1189.
- Shirai M, Hirakawa H, Kimoto M *et al.* (2000) Comparison of whole genome sequences of *Chlamydia pneumoniae* J138 from Japan and CWL029 from USA. *Nucleic Acids Res* **28**: 2311–2314.
- Tabuchi M, Kawai Y, Nishie-Fujita M, Akada R, Izumi T, Yanatori I, Miyashita N, Ouchi K & Kishi F (2009) Development of a novel functional high-throughput screening system for pathogen effectors in the yeast *Saccharomyces cerevisiae*. *Biosci Biotechnol Biochem* **73**: 2261–2267.
- Tabuchi M, Yanatori I, Kawai Y & Kishi F (2010) Retromer-mediated direct sorting is required for proper endosomal

recycling of the mammalian iron transporter DMT1. *J Cell Sci* **123**: 756–766.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. The list of 455 ORFs from *C. pneumoniae* screened by Western blot.

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

The RNA Polymerase PB2 Subunit of Influenza A/HongKong/156/1997 (H5N1) Restrict the Replication of Reassortant Ribonucleoprotein Complexes

Yoko Nakazono, Koyu Hara*, Takahito Kashiwagi, Nobuyuki Hamada, Hiroshi Watanabe

Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, Fukuoka, Japan

Abstract

Background: Genetic reassortment plays a critical role in the generation of pandemic strains of influenza virus. The influenza virus RNA polymerase, composed of PB1, PB2 and PA subunits, has been suggested to influence the efficiency of genetic reassortment. However, the role of the RNA polymerase in the genetic reassortment is not well understood.

Methodology/Principal Findings: Here, we reconstituted reassortant ribonucleoprotein (RNP) complexes, and demonstrated that the PB2 subunit of A/HongKong/156/1997 (H5N1) [HK PB2] dramatically reduced the synthesis of mRNA, cRNA and vRNA when introduced into the polymerase of other influenza strains of H1N1 or H3N2. The HK PB2 had no significant effect on the assembly of the polymerase trimeric complex, or on promoter binding activity or replication initiation activity in vitro. However, the HK PB2 was found to remarkably impair the accumulation of RNP. This impaired accumulation and activity of RNP was fully restored when four amino acids at position 108, 508, 524 and 627 of the HK PB2 were mutated.

Conclusions/Significance: Overall, we suggest that the PB2 subunit of influenza polymerase might play an important role for the replication of reassortant ribonucleoprotein complexes.

Citation: Nakazono Y, Hara K, Kashiwagi T, Hamada N, Watanabe H (2012) The RNA Polymerase PB2 Subunit of Influenza A/HongKong/156/1997 (H5N1) Restrict the Replication of Reassortant Ribonucleoprotein Complexes. *PLoS ONE* 7(2): e32634. doi:10.1371/journal.pone.0032634

Editor: Earl G. Brown, University of Ottawa, Canada

Received: December 14, 2011; **Accepted:** January 28, 2012; **Published:** February 28, 2012

Copyright: © 2012 Nakazono et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants from the Ishibashi Foundation for the Promotion of Science and the Ministry of Education, Science, Sports and Culture, Japan, Grant-in-Aid for Young Scientists (B), 21791015, 2009–2010. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: koyu@med.kurume-u.ac.jp

Introduction

Influenza A virus is a member of the family *Orthomyxoviridae*, and classified into subtypes by antigenic differences of the two surface glycoproteins, the hemagglutinin (HA) and the neuraminidase (NA) [1]. All 16 HA and 9 NA subtypes are maintained in aquatic birds and can be transmitted to various animals, including humans, pigs, horses and birds. However, avian influenza strains usually do not replicate efficiently in humans, and only three subtypes of H1N1, H2N2 and H3N2 have established sustained infection in human populations since the 1918 Spanish influenza, suggesting a significant restriction of transmission and adaptation of avian strains to humans.

The segmented genome structure of influenza virus facilitates genetic reassortment with other influenza strains which is co-infected in the same cells and has played a pivotal role in the emergence of pandemics. The pandemic strains of the past century have incorporated genes expressing the superficial HA and NA glycoproteins giving rise to new subtypes with novel surface antigens. Mutations of avian HA for acquiring human receptor $\alpha 2, 6$ sialic acid binding specificity is a prerequisite for human adaptation. In addition to acquiring novel genes for superficial glycoproteins, at least one internal gene of the RNA polymerase from avian strains has been concurrently incorporated into human

strains. The 1957 and 1968 influenza pandemics coincided with the introduction of an avian PB1 gene [2]. Similarly, the 2009 pandemic was caused by a reassortant that acquired PB2 and PA genes from an avian strain [3,4,5]. However, the contribution of polymerase genes to pandemic emergence has not been elucidated in detail.

The influenza virus RNA polymerase is a heterotrimeric complex composed of three subunits, PB1, PB2 and PA, which assembles with nucleoprotein (NP) and viral RNA, forming ribonucleoprotein complex (RNP) [6,7]. The PB1 subunit contains the S-D-D motif characteristic of polymerases and is directly involved in RNA synthesis [8,9]. The PB2 subunit binds to the cap structure at the 5' end of host mRNA to generate short capped RNA fragments that are used as primers for viral transcription [6,10]. The PA subunit plays a role in transcription and replication through its endonuclease activity [11,12,13], promoter binding [13,14,15,16], cap binding [13] and possible proteolytic activity [17,18]. In addition to the central role of the RNA polymerase in RNA synthesis, recent studies have suggested its potential role in genetic reassortment [19,20,21,22]. Artificial hybrid RNA polymerases between human and avian influenza strains often exhibit a functional loss in RNA replication. Reconstitution experiments of influenza RNP in vivo has demonstrated that an introduction of avian PB2 into a background of human strains has often led to a

severe reduction of the polymerase activity [23,24]. It has also been suggested that a specific combination of avian PB2 with human PA or human PB1 leads to a significant decrease in polymerase activity [24,25]. However, the underlying mechanism that restricts genetic reassortment is still unclear.

In this study, we attempted to characterize and dissect the role of the polymerase genes in giving rise to a functional genetic reassortant. We generated RNP containing hybrid polymerase between human-isolated avian H5N1 and human H1N1 or H3N2. Our results revealed that the PB2 subunit of H5N1 has a strong inhibitory effect on the RNP activity when introduced into the polymerase of other influenza strains. Importantly, H5N1 PB2 could form functional 3P complex properly, but significantly reduced the accumulation of RNP, specifically through the properties of four amino acids in PB2 at position 108, 508, 524 and 627.

Materials and Methods

Strains

cDNA clones isolated from the following influenza strains were used: A/HongKong/156/1997 (H5N1) (abbreviated as HK or H), A/Vietnam/1194/2004 (H5N1) (abbreviated as VN or V), A/WSN/1933 (H1N1) (abbreviated as WSN or W), a newly pandemic A/Kurume/K0910/2009 (H1N1) (abbreviated as SW or S), A/NT/60/1968 (H3N2) (abbreviated as NT or N) [26].

Plasmids

PB1, PB2, PA and NP-expressing plasmids of influenza viruses HK, VN, WSN, SW and NT have previously been described [14,26,27]. The plasmid expressing vRNA of NA gene (vNA) from WSN has also been described previously [28]. Mutants of the PB2 plasmids were prepared by site-directed mutagenesis and were fully sequenced.

RNA isolation and primer extension assay in 293T cell

293T human embryonic kidney cells [12] were transfected with 0.2 µg each of PA, PB1, PB2, NP and vNA expression vector of each strain (WSN, NT, HK, VN or SW) by using Lipofectamine 2000 (Invitrogen). Cells were harvested 30 h posttransfection, and total RNA was isolated with TRIzol reagent (Invitrogen). RNA was then analyzed in a primer extension assay using three primers—one for vRNA, one for mRNA and cRNA, one for 5S rRNA as an internal control [12,13]. Transcripts were visualized by 7% polyacrylamide gel containing 7 M urea in TBE buffer and were detected by autoradiography. Assays were carried out at least three times with independently transfected cells.

Preparation of TAP-tagged polymerase and RNP and in vitro assays

For a preparation of the polymerase, 293T cells were transfected with expression vectors containing PB1, PB2 and TAP-tagged PA subunit of each strain. For a preparation of the RNP, NP and vNA expression vectors were also transfected simultaneously. Cells were harvested 2 days posttransfection and the polymerase or RNP was purified by the tandem affinity purification (TAP) method described previously [27]. Partially purified polymerase or RNP was analyzed by 7.5% SDS-PAGE with silver staining (Invitrogen) and confirmed by western blotting with specific antibody against PB1, PB2 and PA [17,29]. For in vitro assays, the amount of the polymerase was quantitatively adjusted. TAP purification procedure by PA TAP leads to co-purify trimeric complex with PB1-PA TAP heterodimer and PA TAP monomer, and the purified material reveals higher level of

PA than other subunits. Adjustments were made by the quantitative measurements of the level of PB2 on silver-stained SDS-PAGE gel, because PB2 indicates the level of trimeric complex. The dinucleotide initiation of replication assay and UV cross-linking to model vRNA and cRNA promoters were performed as reported previously [16], and quantitated by autoradiography and Quantity One software version 4.6.7 (Bio-Rad).

Results

Effect of individual polymerase subunits of H5N1 on the RNP activity when reconstituted with other polymerase subunits of H1N1 or H3N2

In order to investigate the role of the RNA polymerase on the restriction of genetic reassortment, we reconstituted reassortant RNP by introducing the polymerase subunit of H5N1 into the polymerase of H1N1 or H3N2. We used two human-isolated H5N1 strains of A/HongKong/156/1997 [HK] and a closely related A/Vietnam/1194/04 [VN], two human H1N1 strains of A/WSN/33 [WSN] and the new pandemic influenza A/Kurume/K0910/09 [SW], and H3N2 strain of A/NT/60/68 [NT], because these strains were extensively analyzed previously [14,26]. The RNP was reconstituted in human 293T cells from hybrid polymerase on the background of WSN. The steady-state levels of NA reporter mRNA, vRNA and cRNA were measured by primer extension.

In the case of the HK strain of H5N1 (Figure 1, left 3 panels), the levels of mRNA, cRNA and vRNA were not significantly affected when HK PB1 alone, HK PA alone, HK PB1 - HK PB2 or HK PB1 - HK PA was introduced into WSN polymerase (Figure 1, lane 2, 4, 5 and 7). However, the RNP activity was severely reduced to essentially inactive levels, with only background levels of input vRNA, when either HK PB2 alone or HK PB2 - HK PA was introduced into WSN polymerase (Figure 1, lane 3 and 6). A similar significant reduction of RNP activities was also observed when either HK PB2 alone or HK PB2 - HK PB1 was introduced into SW (Figure 1, lanes 19 and 21) or NT polymerases (Figure 1, lanes 35 and 37). These results apparently showed that HK PB2 was responsible for the severe reduction of RNP activity, because HK PB2 alone could decrease the activity. This reduction of RNP activity was restored by HK PB1 in WSN polymerase (Figure 1, lane 5), or HK PA in SW or NT polymerase (Figure 1, lanes 22 and 38). On the other hand, in the case of the VN strain of H5N1 (Figure 1, right 3 panels), such remarkable reduction of RNP activity by the PB2 subunit was only observed when introduced into NT polymerase (Figure 1, lanes 43 and 45). VN PB2 did not show the inhibitory effect on either WSN or SW polymerases (Figure 1, lane 11, 14, 27 and 29). On the contrary, VN PB2 alone or VN PB2 - VN PB1 significantly increased the activity of SW polymerase (Figure 1, lanes 27 and 29). These results indicate that the PB2 subunits of these two H5N1 strains differ in their properties when reconstituted into hybrid RNP with other influenza strains, and HK PB2 has a strong inhibitory effect on RNP activity.

Rescue of the hybrid RNP activity by mutations in HK PB2

Despite originating from the same H5N1 subtype, the amino acid sequence of PB2 between HK and VN differs at 26 positions out of 759 amino acids (Figure 2A). Since HK PB2 showed a severe reduction in RNP activity when introduced into other polymerases as compared to VN PB2, we speculated that a substitution of these 26 amino acids of HK PB2 for the VN PB2 sequence might rescue the impaired RNP activity. To test this,




Figure 1. Comparison of RNP activities containing hybrid polymerases between H5N1 strains and human strains in vivo. Polymerase subunits of human strains of A/WSN/1933 (H1N1) (W), A/Kurume/K0910/2009 (H1N1) (S) and A/NT/60/1968 (H3N2) (N) were replaced with the corresponding subunits of A/HongKong/156/1997 (H5N1) (H) (left 3 panels) or A/Vietnam/1194/2004 (H5N1) (V) (right 3 panels). The RNP was reconstituted in 293T cells by transfection of plasmids expressing various combinations of polymerase subunits, and WSN derived NP and vNA. Total RNA was extracted 30 h posttransfection. Transcript products of viral mRNA, cRNA and vRNA were measured by primer extension and its positions are indicated on the right. The expected size of mRNA, cRNA, vRNA and 5S rRNA as an internal control are 169–177 nt, 160 nt, 129 nt and 100 nt, respectively.

doi:10.1371/journal.pone.0032634.g001

mutations were systemically introduced into HK PB2 at all positions, except for 4 residues at positions 190, 299, 340 and 355 because they were similar basic (R and K) amino acids. Firstly, we focused on residues 189 to 199 because amino acid differences between HK PB2 and VN PB2 were clustered in this region. However, all mutant polymerases K189E, K194Q, N195D, N197K and S199A showed still inactive levels of the RNP activity comparable to WT HK PB2 (Figure 2B, lanes 2 to 7). Next, we

focused on residue 627 because PB2 K627 is known to be an important determinant for the virulence and host adaptation of influenza virus. A mutant polymerase E627K of HK PB2 rescued significant activity and the levels of all 3 RNA species (mRNA, cRNA and vRNA) reached about 50% of the VN PB2 activity (Figure 2B, compare lanes 17 with lane 10). In order to attempt to rescue RNP activity further, we then introduced additional mutations into the E627K mutant one by one. Mutations at C-

A

subtype	strain	64	105	108	147	189	190	194	195	197	199	292	299	334	336	340	355	381	508	524	567	590	627	655	661	667	717
H5N1	HK	M	T	T	M	K	R	K	N	N	S	V	K	K	F	R	K	M	Q	M	E	S	E	A	T	I	T
	VN	I	A	A	I	E	K	Q	D	K	A	I	R	S	S	K	R	L	R	T	D	G	K	V	A	V	A
						*					*			*	*												

B




Figure 2. Effects of mutations in the HK PB2 subunit on the impaired RNP activity reconstituted from hybrid polymerase. (A) Alignment of amino acid residues of PB2 subunit differing between HK and VN of H5N1 strains. All positions of HK PB2, except for 4 residues (asterisk) that were similar basic amino acids, were sequentially substituted for VN PB2 sequences. **(B)** Steady state level of NA vRNA, mRNA, and cRNA in WSN (W) RNP reconstituted from hybrid polymerase by replacing only PB2 subunit with the HK PB2 wild type (H) (lanes 2 and 9), HK PB2 mutants (lanes 3–7, 10–16, 18–20, 22–26 and 28–30) and VN PB2 (V) (lanes 17, 21, 27 and 31). The numbers in HK PB2 mutants indicate mutated positions in HK PB2. Arrows indicate HK PB2 mutants which showed significant increase of RNP activity. The positions found to be important for the rescue of the RNP activity are highlighted. doi:10.1371/journal.pone.0032634.g002

terminal regions did not further increase the RNP activity (Figure 2B, lanes 11–16). However, the additional mutation at M524T significantly increased activity, specifically of cRNA and vRNA, reaching the equivalent level to VN PB2 (Figure 2B, compare lanes 19 with 21). Subsequent mutation at Q508R further slightly increased vRNA to higher levels than VN PB2 (Figure 2B, lane 20), although the mRNA level was still lower than VN PB2. These results suggest a specific role of the positions 508 and 524 on the RNA replication (cRNA and vRNA synthesis), not on transcription (mRNA synthesis). The level of mRNA was fully rescued and the level of all three RNA species nearly reached the VN PB2 level when a mutation was subsequently introduced at

T108A (Figure 2B, lane 24). Additional mutations did not increase the RNP activity further (Figure 2B, lanes 25–31). Overall, we conclude that at least 4 positions of 108, 508, 524 and 627 in HK PB2 are responsible for the impaired RNP activity reconstituted from hybrid polymerase.

Mutations at position 108, 508, 524 and 627 in VN PB2 impair the RNP activity

Since four amino acids in HK PB2 were found to be critical for rescuing activity of the hybrid RNP, it is conceivable that substitution of amino acids at the same position in VN PB2 by the HK PB2 sequence might decrease the RNP activity. Single

mutant R508Q or double mutant R508Q/T524M showed a slight decrease in activity compared with VN PB2 (Figure 3, lanes 3 and 4), while single mutant K627E showed a significant decrease in activity to less than 30% of mRNA, and ~10% of cRNA and vRNA (Figure 3, lane 5). The synthesis of all three RNA species was further decreased in a double mutant R508Q/K627 (Figure 3, lane 7), and markedly reduced to undetectable levels in a fourfold mutant A108T/R508Q/T524M/K627E (Figure 3, lane 9). Taken together, these results support our conclusion that 4 positions at 108, 508, 524 and 627 in HK PB2 are responsible for the optimal activity of RNP reconstituted from hybrid polymerase. We cannot exclude the possibility that residues other than 108, 508, 524 and 627 may also be important for RNP activity, because we have not tested HK PB2 carrying mutations at only these 4 positions.

HK PB2 impairs neither the assembly of trimeric complex nor the in vitro polymerase activity

To address the question why HK PB2 severely inhibited the activity of RNP reconstituted from hybrid polymerase, we initially examined whether HK PB2 affects the correct assembly of the trimeric complex of PB1, PB2, and PA. To allow the purification of trimeric complex, a C-terminally TAP-tagged PA was co-expressed with PB1 and PB2 in 293T cells, and the trimeric complex was affinity purified by a TAP method and quantitatively adjusted (see materials and methods). In the case of HK PB2, the expression level of three subunits was comparable to WSN polymerase or VN PB2 hybrid polymerase (Figure 4A, lane 2), although its RNP activity was impaired. A similar expression level of three subunits was observed in all four HK PB2 mutants having significant RNP activity (Figure 4A, lanes 3–6). Thus, HK PB2 does not appear to affect the correct assembly of the trimeric complex.

An alternative explanation for the defect of RNP activity is a loss of the polymerase activity. The binding of RNA polymerase to the promoter is an essential step to initiate RNA synthesis. Therefore, the promoter binding activity of the polymerase in vitro

was assayed by UV cross-linking, then subsequent initiation of RNA synthesis was analyzed by dinucleotide replication assay (see materials and methods). Surprisingly, HK PB2 WT showed a strong activity to bind both vRNA and cRNA promoters (>200% of VN PB2 [Figure 4B and 4D, lane 2]), in spite of the loss of the RNP activity. However, the K627E mutation significantly reduced vRNA and cRNA promoter binding activities to the level of VN PB2 (100–150% of VN PB2 [Figure 4B and 4D, lane 3]). This suggests that position 627 might be involved in promoter binding. Additional mutations did not further affect promoter binding (Figure 4B and 4D, lanes 4–6). The promoter binding activity of the polymerase correlated well with the replication initiation activity and essentially similar results were observed. HK PB2 WT synthesized significant yields of ApG in both vRNA and cRNA templates (>200% of VN PB2 [Figure 4C and 4E, lane 2]). However, K627E mutation remarkably reduced the replication initiation activity (approximately 150% of VN PB2 [Figure 4C and 4E, lane 3]). Additional mutations had little effect on the activity (Figure 4C and 4E, lanes 4–6). Overall these results suggest that the impaired RNP activity by HK PB2 was not due to the defect in the assembly of the polymerase and the loss of the in vitro polymerase activity.

HK PB2 impairs the accumulation of ribonucleoprotein complex

Another possible explanation for the loss of RNP activity is a defect in the assembly of RNP. To test this possibility, we purified and evaluated the amount of RNP accumulated in vivo. To allow RNP purification, a C-terminally TAP-tagged PA was coexpressed and the reconstituted RNP was affinity purified by a TAP method (see materials and methods). The amount of TAP-purified RNP was measured by Western blotting with specific antibodies for NP (Figure 5B and 5D). Addition of a C-terminal TAP tag at PA did not interfere with the RNP activity (data not shown). In the case of hybrid RNP containing VN PB2, NP was clearly detected, with an essentially similar level to that of WSN PB2 (Figure 5B and 5D, lanes 1 and 5). This indicates that the VN PB2 does not affect in vivo accumulation of RNP. By contrast, in the hybrid containing the HK PB2 (Figure 5A, lane 2) insignificant levels of RNP were detected (Figure 5B and 5D, lane 2), indicating the defect in the replication of RNP. Nevertheless the trimeric complex was correctly formed (Figure 5A, lane 2) and overall NP was expressed at equivalent levels to those seen in the wild-type WSN or VN (Figure 5C, lane 2 compared with lanes 1 and 5). These results clearly showed that HK PB2 had a major inhibitory effect on the accumulation of hybrid RNP. Importantly, the single mutation at 627 rescued significant accumulation of RNP, with an essentially similar level to that of VN PB2 (Figure 5B and 5D, lanes 3 and 5), suggesting that position 627 is obviously involved in the accumulation of RNP. However, the single mutation at 627 did not fully rescue the RNP activity and additional mutation at 108, 508 and 524 were required for the full activity (Figure 2). A significant level of RNP accumulation comparable to that of WSN PB2 or VN PB2 was also observed in the HK PB2 mutant with full RNP activity (Figure 5B and 5D, lane 4). Overall, these results suggested that HK PB2 significantly impairs the accumulation of RNP, explaining the loss of the RNP activity.




Figure 3. Effects of mutations in the VN PB2 subunit on the RNP activity reconstituted from hybrid polymerase. RNP of WSN (W) was reconstituted from hybrid polymerase by replacing only PB2 subunit with the VN PB2 wild type (V) (lane 2) or VN PB2 mutants (lanes 3–9). The steady state level of vRNA, mRNA, and cRNA was measured by primer extension. The numbers indicate mutated positions in VN PB2. doi:10.1371/journal.pone.0032634.g003

Discussion

The genetic reassortment between two different influenza A viruses can generate 256 (2^8) genotypes theoretically. However, systematic studies by using reverse genetics have shown that the number of replicative reassortant viruses is apparently limited




Figure 4. Promoter binding activity and replication initiation activity of HK PB2 mutants. (A) Partially purified polymerases analyzed by silver-stained 7.5% SDS-PAGE. Hybrid WSN (W) polymerase replaced only PB2 subunit with HK PB2 wild type (H) (lanes 2), HK PB2 mutants (lanes 3–6) and VN PB2 (V) (lane 7) was transiently expressed in 293T cells and partially purified by using TAP-tagged PA (see materials and methods). The numbers in HK PB2 mutants indicate mutated positions in HK PB2. The highlighted numbers are important for the rescue of the RNP activity. (B) UV cross-linking of model vRNA and cRNA promoters to hybrid polymerases. Purified and quantified polymerases were incubated with 32 P-labelled 3' strand of the vRNA promoter in the presence of the unlabelled 5' strand of the vRNA promoter (upper panel), or 32 P-labelled 3' strand of the cRNA promoter in the presence of the unlabelled 5' strand of the cRNA promoter (lower panel). Lane numbers correspond to the numbers in (A). The positions of the cross-linked products are indicated on the right. (C) ApG synthesis with a model vRNA promoter (upper panel) or cRNA promoter (lower panel). Lane numbers correspond to the numbers in (A). The position of the specific ApG product is indicated on the right. (D and E) Quantification of results obtained in panels B and C, respectively, by phosphorimaging. Data are expressed as percentages relative to VN PB2 (lane 7) (mean \pm standard deviation; $n=3$). Black bars, model vRNA promoter; white bars, model cRNA promoter. * shows statistical significance at $P<0.01$ in a Student's t-test.

doi:10.1371/journal.pone.0032634.g004

[23,25,30]. Reassortment between A/Thailand/16/04 (H5N1) and A/Wyoming/3/03 (H3N2), or A/equine/Prague/1/56 (H7N7) and A/Yokohama/2017/03 (H3N2), could yield only 63 (254 parent virus) or 29 (256 parent virus) hybrid genotypes, respectively [23,25]. In this study, we focused on the role of the RNA polymerase on the restriction of genetic reassortment of influenza virus. We constructed artificial hybrid RNPs by replacing the polymerase subunits of H1N1 or H3N2 with the corresponding subunits from two strains of H5N1, HK and VN, and evaluated the RNP activity by measuring steady state levels of mRNA, vRNA and cRNA. We found that the PB2 subunit of HK had a strong inhibitory effect on the activity both in transcription (mRNA synthesis) and replication (cRNA and vRNA synthesis), because it alone could inhibit the activity of all other strains (Figure 1). HK PB1 and HK PA did not appear to have this effect. These results are consistent with the observation that the PB2 subunit of avian or pandemic H1N1 has often lead to a reduction of activity in hybrid polymerase with human strains [23,24,31]. Interestingly, the pandemic human H2N2 and H3N2 does not carry avian PB2. Thus, we suggest that an introduction of the PB2 from certain avian H5N1 strains into human strains might be a disadvantage for successful genetic reassortment. Our results cannot exclude the possibility that NP may be involved, because other reassortment studies suggested the importance of NP in host adaptation [30,32,33,34].

Although few studies have described the mechanism of restriction of genetic reassortment, the loss of RNP activity in a hybrid experiment between equine H7N7 and human H3N2 strains was linked to the inability of assembly of the polymerase

trimeric complex [25]. On the contrary, the polymerase trimeric complex was properly formed and no significant reduction of the in vitro polymerase activity was seen, even though the RNP activity was impaired when HK PB2 was introduced into the polymerase of other influenza strains (Figure 5). Our results clearly showed that the defect of RNP activity is related to poor accumulation of RNP. The RNP is formed by the association of vRNA to NP and polymerase trimeric complex. We can only speculate that HKPB2 may affect the efficiency of interactions of the polymerase with NP [35,36], vRNA and cellular factors [37,38] which are involved in the RNP assembly, thereby affecting RNP accumulation.

The correlation between the presence of lysine at position 627 of PB2 and the efficiency of RNP accumulation has recently been reported for H1N1 strains. The K \rightarrow E mutation at PB2 627 of human strain A/WSN/1933 (H1N1) significantly decreased the accumulation of RNP reconstituted in human 293T cells and resulted in the concomitant decrease in the RNP activity [39]. In addition, the E \rightarrow K mutation at PB2 627 of avian strain A/Mallard/Marquenterre/MZ237/1983 (H1N1) in 293T cells increased the accumulation of RNP [19]. These observations are in agreement with our data in H5N1 strains, indicating that the accumulation of RNP was almost fully rescued by the E \rightarrow K mutation at 627. However, the single mutation at 627 could only partially rescue the RNP activity, and an additional mutation at 108, 508 and 524 was required for full recovery of the RNP activity (Figure 2). Thus, it is possible that amino acid at PB2 627 is mainly involved in the structural assembly of RNP, but other positions 108, 508 and 524 also play an important role in




Figure 5. Accumulation of RNP reconstituted from hybrid polymerase. Hybrid RNP was reconstituted in a background of WSN (W) by replacing only PB2 subunit with the HK PB2 wild type (H) (lanes 2), HK PB2 mutants (lanes 3–4) and VN PB2 (V) (lanes 5). Reconstituted RNP in 293T cells was partially purified by using TAP-tagged PA (see materials and methods). The numbers in HK PB2 mutants indicate mutated positions in HK PB2. **(A and B)** Partially purified RNP analyzed by silver-stained 7.5% SDS-PAGE, and by western blotting using specific antibodies for NP, respectively. **(C)** Expression of NP in total cell lysate, analyzed by western blotting using specific antibodies for NP by 7.5% SDS-PAGE. The positions of PB1, PB2, PA-TAP and NP are shown on the right. **(D)** Quantification of results obtained in panel B by phosphorimaging. Data are expressed as percentages relative to VN PB2 (lane 5) (mean \pm standard deviation; $n=3$). * shows statistical significance at $P<0.01$ in a Student's *t*-test. doi:10.1371/journal.pone.0032634.g005

modulating the function of assembled RNP. Position 108 may modulate the interaction with PB1 and preferentially affect transcriptional activity (Figure 2, lane 24), since it is close to the PB1 binding site (Figure 6A) [29,40]. Positions 508 and 524 are close to cap-binding sites [10,41] and the 627 domain (538–693) [42]. These positions, we speculate, may affect RNA binding, the function of 627 residue, or may modulate the interaction with host chaperone proteins, such as Hsp90, Hsp70 and CCT [43,44,45]. Importantly, an alignment of the PB2 sequences from typical human influenza viruses and avian influenza viruses currently circulating in poultry in some countries, with differing HA and NA subtypes, demonstrated that three positions 108, 508 and 524 were highly conserved among influenza A viruses (Figure 6B). This suggests that these residues are important for the function of RNP in influenza A viruses. In addition, an alignment of HK PB2 sequence with 60 human isolates of H5N1 demonstrated that Q508 and M524 were conserved only less than 2%. Perhaps, these residues might define specific features of HK PB2.

The E→K mutation at HK PB2 627 showed a significant reduction in vRNA promoter and cRNA promoter bindings in cross-linking experiments (Figure 4B). PB2 has been shown to bind both vRNA and cRNA promoters [16,40], but the precise binding site in PB2 has not yet been identified. Our findings suggest that the PB2 627 is involved in vRNA and cRNA promoter binding. A reduction of the promoter binding is clearly consistent with the

reduction of replication initiation activity *in vitro* (Figure 4C). Structural studies of the C-terminal region of PB2 have shown that the K→E mutation at PB2 627 disrupts the positively charged surface of the protein without altering structure [42]. We propose that the mutation at HK PB2 627 alter the charge of the protein, thereby affecting the promoter binding and subsequent RNA synthesis.

A purified H5N1 polymerase shows significantly higher polymerase activity *in vitro* when compared to human strain A/WSN/33 (H1N1) [14,46,47]. The polymerase activity of WSN was increased by the introduction of the PB2 or PA subunit of H5N1. These findings are consistent with our observations that the HK PB2 remarkably enhanced the promoter binding activity and replication initiation activity of WSN polymerase (Figure 4). However, the HK PB2 significantly reduced the polymerase activity *in vivo* in the RNP reconstitution assay. This different result between *in vitro* and *in vivo* is also in agreement with the previous reports [14,47]. We speculate that a significant reduction of the polymerase activity *in vivo*, in spite of its strong activity *in vitro*, could be explained by the poor accumulation of RNP.

Introduction of HK PA into SW and NT polymerases increased the synthesis of mRNA, cRNA and vRNA (Figure 1, lanes 20 and 36). It is also worth noting that HK PA obviously relieved the inhibitory effect of HK PB2 (Figure 1, lanes 22 and 38). This suggests a functional cooperation between PB2 and PA [48].




Figure 6. Alignment of PB2 subunit. (A) Functional map of PB2 subunit. (B) Alignment of amino acid residues in PB2 which are important for the accumulation of RNP. * shows influenza strains used in this study. Gray shading indicates high evolutionary conservation between influenza A, B and C virus sequences.

doi:10.1371/journal.pone.0032634.g006

These results are consistent with recent RNP reconstitution studies suggesting that PA plays a major role in increasing activities of hybrid polymerase [14,47,49]. However, such a tendency could not be observed in hybrid WSN polymerase, suggesting that the PA subunit cannot always overcome the restriction of genetic reassortment.

In summary, we have found that the PB2 subunit of influenza A/HongKong/156/1997 (H5N1) has a strong inhibitory effect on the RNP activity when introduced into the polymerase of other influenza strains. In addition, four residues at positions 108, 508, 524 and 627 of the PB2 subunit appear to be important determinants that are involved in the accumulation of functional RNP and in modulating the polymerase activity. These results may suggest a possible mechanism by which the generation of replicative reassortant virus of influenza is highly restricted.

References

- Peter P, Megan SL (2007) *Orthomyxoviridae: the viruses and their replication*. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, et al. (2007) *Fields virology*, 5th ed. PhiladelphiaPa: Lippincott Williams & Wilkins. pp 1647–1689.
- Kawaoka Y, Krauss S, Webster RG (1989) Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. *J Virol* 63: 4603–4608.
- Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 360: 2605–2615.
- Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. *Nature* 460: 1021–1025.
- Peiris JS, Poon LL, Guan Y (2009) Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. *J Clin Virol* 45: 169–173.
- Engelhardt OG, Fodor E (2006) Functional association between viral and cellular transcription during influenza virus infection. *Rev Med Virol* 16: 329–345.
- Resa-Infante P, Jorba N, Coloma R, Ortin J (2011) The influenza virus RNA synthesis machine: advances in its structure and function. *RNA Biol* 8: 207–215.
- Biswas SK, Nayak DP (1994) Mutational analysis of the conserved motifs of influenza A virus polymerase basic protein 1. *Journal of virology* 68: 1819–1826.
- Poch O, Sauvaget I, Delarue M, Tordo N (1989) Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. *The EMBO journal* 8: 3867–3874.
- Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, et al. (2008) The structural basis for cap binding by influenza virus polymerase subunit PB2. *Nat Struct Mol Biol* 15: 500–506.
- Dias A, Bouvier D, Crepin T, McCarthy AA, Hart DJ, et al. (2009) The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. *Nature* 458: 914–918.
- Fodor E, Crow M, Mingay LJ, Deng T, Sharps J, et al. (2002) A single amino acid mutation in the PA subunit of the influenza virus RNA polymerase inhibits endonucleolytic cleavage of capped RNAs. *J Virol* 76: 8989–9001.
- Hara K, Schmidt FI, Crow M, Brownlee GG (2006) Amino acid residues in the N-terminal region of the PA subunit of influenza A virus RNA polymerase play a critical role in protein stability, endonuclease activity, cap binding, and virion RNA promoter binding. *J Virol* 80: 7789–7798.

Acknowledgments

We thank Prof. George G Brownlee (University of Oxford), Prof. Ervin Fodor (University of Oxford) and Prof. Tao Deng (Chinese Academy of Medical Sciences and Peking Union Medical College) for critical reading of the manuscript and helpful discussions.

Author Contributions

Conceived and designed the experiments: KH YN NH HW. Performed the experiments: YN KH TK. Analyzed the data: YN KH TK. Contributed reagents/materials/analysis tools: YN KH TK. Wrote the paper: KH.

14. Kashiwagi T, Leung BW, Deng T, Chen H, Brownlee GG (2009) The N-terminal region of the PA subunit of the RNA polymerase of influenza A/HongKong/156/97 (H5N1) influences promoter binding. *PLoS One* 4: e5473.
15. Lee MT, Bishop K, Medcalf L, Elton D, Digard P, et al. (2002) Definition of the minimal viral components required for the initiation of unprimed RNA synthesis by influenza virus RNA polymerase. *Nucleic Acids Res* 30: 429–438.
16. Maier HJ, Kashiwagi T, Hara K, Brownlee GG (2008) Differential role of the influenza A virus polymerase PA subunit for vRNA and cRNA promoter binding. *Virology* 370: 194–204.
17. Hara K, Shiota M, Kido H, Ohisu Y, Kashiwagi T, et al. (2001) Influenza virus RNA polymerase PA subunit is a novel serine protease with Ser624 at the active site. *Genes Cells* 6: 87–97.
18. Sanz-Ezquerro JJ, Zurcher T, de la Luna S, Ortin J, Nieto A (1996) The amino-terminal one-third of the influenza virus PA protein is responsible for the induction of proteolysis. *J Virol* 70: 1905–1911.
19. Labadie K, Dos Santos Afonso E, Rameix-Welti MA, van der Werf S, Naffakh N (2007) Host-range determinants on the PB2 protein of influenza A viruses control the interaction between the viral polymerase and nucleoprotein in human cells. *Virology* 362: 271–282.
20. Naffakh N, Massin P, Escrivo N, Crescenzo-Chaigne B, van der Werf S (2000) Genetic analysis of the compatibility between polymerase proteins from human and avian strains of influenza A viruses. *The Journal of general virology* 81: 1283–1291.
21. Naffakh N, Tomoiu A, Rameix-Welti MA, van der Werf S (2008) Host restriction of avian influenza viruses at the level of the ribonucleoproteins. *Annual review of microbiology* 62: 403–424.
22. Rameix-Welti MA, Tomoiu A, Dos Santos Afonso E, van der Werf S, Naffakh N (2009) Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection. *Journal of virology* 83: 1320–1331.
23. Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO (2008) Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. *PLoS Pathog* 4: e1000072.
24. Li OT, Chan MC, Leung CS, Chan RW, Guan Y, et al. (2009) Full factorial analysis of mammalian and avian influenza polymerase subunits suggests a role of an efficient polymerase for virus adaptation. *PLoS One* 4: e5658.
25. Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y (2008) Compatibility among polymerase subunit proteins is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses. *J Virol* 82: 11880–11888.
26. Kashiwagi T, Hara K, Nakazono Y, Hamada N, Watanabe H (2010) Artificial hybrids of influenza A virus RNA polymerase reveal PA subunit modulates its thermal sensitivity. *PLoS One* 5: e15140.
27. Deng T, Sharps J, Fodor E, Brownlee GG (2005) In vitro assembly of PB2 with a PB1-PA dimer supports a new model of assembly of influenza A virus polymerase subunits into a functional trimeric complex. *J Virol* 79: 8669–8674.
28. Vreede FT, Jung TE, Brownlee GG (2004) Model suggesting that replication of influenza virus is regulated by stabilization of replicative intermediates. *J Virol* 78: 9568–9572.
29. Toyoda T, Adyshev DM, Kobayashi M, Iwata A, Ishihama A (1996) Molecular assembly of the influenza virus RNA polymerase: determination of the subunit-subunit contact sites. *J Gen Virol* 77(Pt 9): 2149–2157.
30. Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, et al. (2010) Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. *Proc Natl Acad Sci U S A* 107: 4687–4692.
31. Octaviani CP, Goto H, Kawaoka Y (2011) Reassortment between Seasonal H1N1 and Pandemic (H1N1) 2009 Influenza Viruses Is Restricted by Limited Compatibility among Polymerase Subunits. *J Virol* 85: 8449–8452.
32. Bean WJ (1984) Correlation of influenza A virus nucleoprotein genes with host species. *Virology* 133: 438–442.
33. Scholtissek C, Burger H, Kistner O, Shortridge KF (1985) The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. *Virology* 147: 287–294.
34. Snyder MH, Buckler-White AJ, London WT, Tierney EL, Murphy BR (1987) The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys. *J Virol* 61: 2857–2863.
35. Biswas SK, Boutz PL, Nayak DP (1998) Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. *J Virol* 72: 5493–5501.
36. Poole E, Elton D, Medcalf L, Digard P (2004) Functional domains of the influenza A virus PB2 protein: identification of NP- and PB1-binding sites. *Virology* 321: 120–133.
37. Engelhardt OG, Smith M, Fodor E (2005) Association of the influenza A virus RNA-dependent RNA polymerase with cellular RNA polymerase II. *Journal of virology* 79: 5812–5818.
38. Jorba N, Juarez S, Torreira E, Gastaminza P, Zamarrero N, et al. (2008) Analysis of the interaction of influenza virus polymerase complex with human cell factors. *Proteomics* 8: 2077–2088.
39. Mehle A, Doudna JA (2008) An inhibitory activity in human cells restricts the function of an avian-like influenza virus polymerase. *Cell host & microbe* 4: 111–122.
40. Jung TE, Brownlee GG (2006) A new promoter-binding site in the PB1 subunit of the influenza A virus polymerase. *J Gen Virol* 87: 679–688.
41. Fechter P, Mingay L, Sharps J, Chambers A, Fodor E, et al. (2003) Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding. *J Biol Chem* 278: 20381–20388.
42. Tarendeau F, Crepin T, Guilligay D, Ruigrok RW, Cusack S, et al. (2008) Host determinant residue lysine 627 lies on the surface of a discrete, folded domain of influenza virus polymerase PB2 subunit. *PLoS Pathog* 4: e1000136.
43. Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, et al. (2002) Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. *J Biol Chem* 277: 45306–45314.
44. Hirayama E, Atagi H, Hiraki A, Kim J (2004) Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex. *J Virol* 78: 1263–1270.
45. Fislava T, Thomas B, Graef KM, Fodor E (2010) Association of the influenza virus RNA polymerase subunit PB2 with the host chaperonin CCT. *J Virol* 84: 8691–8699.
46. Bradel-Trethewey BG, Kelley Z, Chakraborty-Sett S, Takimoto T, Kim B, et al. (2008) The human H5N1 influenza A virus polymerase complex is active in vitro over a broad range of temperatures, in contrast to the WSN complex, and this property can be attributed to the PB2 subunit. *The Journal of general virology* 89: 2923–2932.
47. Leung BW, Chen H, Brownlee GG (2010) Correlation between polymerase activity and pathogenicity in two duck H5N1 influenza viruses suggests that the polymerase contributes to pathogenicity. *Virology* 401: 96–106.
48. Hemerka JN, Wang D, Weng Y, Lu W, Kaushik RS, et al. (2009) Detection and characterization of influenza A virus PA-PB2 interaction through a bimolecular fluorescence complementation assay. *Journal of virology* 83: 3944–3955.
49. Mehle A, Doudna JA (2009) Adaptive strategies of the influenza virus polymerase for replication in humans. *Proc Natl Acad Sci U S A* 106: 21312–21316.

Antimicrobial susceptibility and genetic characteristics of *Haemophilus influenzae* isolated from community-acquired respiratory tract infection patients in Shanghai City, China

Liang Qin · Zhaoyan Zhou · Bijie Hu ·
Taro Yamamoto · Hiroshi Watanabe

Received: 2 November 2011 / Accepted: 12 January 2012 / Published online: 4 February 2012
© Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2012

Abstract *Haemophilus influenzae* is an important causative pathogen of community-acquired respiratory infection in China. In this study we investigated 37 *H. influenzae* strains isolated from patients with community-acquired respiratory tract infections (CARTI) in Shanghai city between Dec 2008 and Apr 2009. *H. influenzae* clinical isolates were identified, and β -lactamase production tests were conducted and minimal inhibitory concentrations (MIC) were measured. Pulsed-field gel electrophoresis (PFGE) was introduced as an effective fingerprinting method. Two isolates (5.4%) were verified as serotype b strains, and 30 strains (81.1%) were nontypeable *H. influenzae*. Furthermore, 10 (27.0%) were β -lactamase-producing ampicillin-resistance (BLPAR) (TEM-1 type) strains, 11 (29.8%) were low- β -lactamase-nonproducing

ampicillin-resistant *H. influenzae* (Low-BLNAR) strains, and the rest were β -lactamase-negative ampicillin-susceptible (BLNAS) strains. Minimum inhibitory concentrations (MIC₉₀; μ g/ml) were 2 for ampicillin/sulbactam, 0.05 for cefotaxime, 16 for cefaclor, 2 for azithromycin, 0.12 for levofloxacin, and 4 for imipenem. Fingerprint typing by PFGE revealed 23 independent patterns for the isolates. Pattern A (defined in this study) was predominant in BLPAR strains, and a variety of other patterns were detected in Low-BLNAR and BLNAS strains. Although the incidence of ampicillin resistant *H. influenzae* is increasing in CARTI patients in China, current antimicrobial chemotherapy seems to be effective.

Keywords Antimicrobial susceptibility · *Haemophilus influenzae* · BLPAR and Low-BLNAR · PFGE

Abbreviations

ABPC/SBT	Ampicillin/sulbactam
AZM	Azithromycin
BLNAR	β -lactamase-nonproducing ampicillin-resistant <i>Haemophilus influenzae</i>
BLNAS	β -lactamase-nonproducing ampicillin-susceptible <i>Haemophilus influenzae</i>
BLPAR	β -lactamase-producing ampicillin-resistant <i>Haemophilus influenzae</i>
CAP	Community-acquired pneumonia
CARTI	Community-acquired respiratory tract infections
CCL	Cefaclor
CLSI	Clinical and Laboratory Standards Institute
CTX	Cefotaxime
Hib	Serotype b <i>Haemophilus influenzae</i>
IPM	Imipenem

Some of the results obtained in this study were presented at the 59th annual meeting of the Japanese Society of chemotherapy, and all the results obtained in this study have been submitted to forthcoming 86th annual meeting of the Japanese Association for Infectious Diseases for an oral presentation in April 2012.

L. Qin (✉) · H. Watanabe
Division of Infectious Diseases, Department of Infectious
Medicine, Kurume University School of Medicine,
67 Asahi-Machi, Kurume, Fukuoka 830-0011, Japan
e-mail: shin_ryou@med.kurume-u.ac.jp

Z. Zhou · B. Hu
Department of Pulmonary Medicine, Zhongshan Hospital
of Fudan University, Shanghai, China

T. Yamamoto
Department of International Health, Institute of Tropical
Medicine, Nagasaki University, Nagasaki, Japan

Low-BLNAR	Low β -lactamase-nonproducing ampicillin-resistant <i>Haemophilus influenzae</i>
LVFX	Levofloxacin
MIC	Minimum inhibitory concentration
NTHi	Nontypeable <i>Haemophilus influenzae</i>
PBPs	Penicillin-binding proteins
PFGE	Pulsed-field gel electrophoresis

Introduction

Haemophilus influenzae is a pleomorphic Gram-negative coccobacillus which is regarded as an important community acquired pathogen. *H. influenzae* initially colonizes the nasopharynx, and naturally-acquired disease caused by *H. influenzae* seems to occur only in humans [1]. Six serotypes (a–f) have been identified on the basis of capsular polysaccharides. *H. influenzae* type b (Hib) seems to be the most important serotype involved in childhood pneumonia, meningitis, and bacteremia. However, Nontypeable *H. influenzae* (NTHi) is reported to cause otitis media, sinusitis in children, and is associated with community-acquired pneumonia (CAP) [2] and acute exacerbations of chronic bronchitis [3, 4]. Because ampicillin has long been used as the first drug of choice for treatment of *H. influenzae* infections, TEM-1 and ROB-1 type β -lactamase-positive ampicillin-resistant (BLPAR) strains are identified in almost all isolates with reduced susceptibility to ampicillin. Furthermore, β -lactamase-negative ampicillin-resistant (BLNAR) strains have recently been reported to have a mechanism of resistance that reduces the affinity of ampicillin for penicillin-binding proteins (PBPs) [5, 6]. The global prevalence of BLNAR strains remains low [7–9], but in some countries, for example Japan, BLNAR strains are encountered with increasing frequency [10–12]. In China, many studies have reported that *H. influenzae* was frequently discovered in CAP patients, and the proportion of ampicillin-resistant strains in isolates had increased steadily from 8.5 to 14.8% [13, 14] in adults and from 2.4–14.5% in children [15, 16]. Nevertheless, clinical details about antimicrobial-resistant strains, for example BLNAR and BLPAR, are still limited in China. Furthermore, *H. influenzae* isolates analyzed in most studies were provided by central hospitals affiliated with universities which usually only admit critical patients, and most of these had already received chemotherapy. The characteristics of the spread of *H. influenzae* in communities are still unclear. This study was conducted to address such issues.

Materials and methods

Study sites

Eleven hospitals cooperated in this study between December 2008 and April 2009. These facilities are community-level hospitals, with fewer than 200 beds, located in 11 independent districts of Shanghai city. During the study period, Outpatients diagnosed with community-acquired respiratory tract infection (CARTI) caused by *H. influenzae* were included in this study. Biological specimens were collected from all participants during a hospital visit (usually the first visit). Clinical specimens (including sputa and throat swabs) were sent to the clinical microbiology laboratory at Zhongshan hospital where the *H. influenzae* isolates were identified.

Bacterial strains

Gram-stained smears and cultures of specimens, obtained as recently as possible, were prepared to identify *H. influenzae* isolates. Isolates were inoculated on chocolate agar plates and cultured at 37°C overnight in 5% CO₂ for subculture. β -lactamase production was detected by means of a disc impregnated with nitrocefin (Becton–Dickinson, Sparks, MD, USA). Serotyping was performed by slide agglutination with antisera purchased from Difco Laboratories (Detroit, MI, USA).

Antimicrobial susceptibility test

Minimum inhibitory concentration (MIC) was determined by the broth-dilution method, in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [17]. The susceptibility of 37 *H. influenzae* isolates was tested against 6 antibiotics: ampicillin/sulbactam (ABPC/SBT), cefotaxime (CTX), cefaclor (CCL), azithromycin (AZM), levofloxacin (LVFX), and imipenem (IPM) (Oxoid, UK). *H. influenzae* ATCC 49247 was also tested as the reference strain.

Genetic identification of antimicrobial resistance-related genes

PCR was performed on 37 *H. influenzae* isolates to identify antimicrobial resistance-related genes, in accordance with the manufacturer's manual (Wakunaga Pharmaceutical, Hiroshima, Japan), as described elsewhere [18, 19]. P6 primers were used to amplify the P6 gene which encodes the P6 membrane protein specific for *H. influenzae*, TEM-I primers to amplify part of the *bla*_{TEM-1} gene, PBP3-S primers to identify an Asn526 → Lys amino acid substitution in the *ftsI* gene, and PBP3-BLN primers to identify

an Asn526 → Lys and Ser385 → Thr amino acid substitution in the *ftsI* gene.

Pulsed-field gel electrophoresis

Pulsed-field gel electrophoresis (PFGE) was performed on all the strains to determine genetic relatedness, as described elsewhere [20, 21]. The DNA was digested with *Sma* I (Takara Shuzo, Shiga, Japan). CHEF Mapper Pulsed Field Electrophoresis Systems (Bio-Rad Life Science Group, Hercules, CA, USA) were used for the electrophoresis, with a potential of 6 V/cm, switch times of 0.47 and 63 s, and a run-time of 20 h and 18 min. After staining with Ethidium bromide, interpretation of PFGE patterns was based on the criteria described by Tenover et al. [22].

Results

Characteristics of the strains

This study included 37 patients (male 18, female 19) diagnosed as CARTI (including 18 acute pharyngitis, 2 acute tonsillitis, 11 acute bronchitis, 2 acute pneumonia, and 4 exacerbation of bronchiectasis). The average age was 55.4 years (17–99). Only 6 patients with underlying diseases (chronic cardiac disease, hypertension, diabetes mellitus, and chronic pulmonary diseases) were recorded. None of the patients had received any antibiotic therapy before the specimens were obtained. A total of 37 *H. influenzae* isolates were isolated from these patients. Of these, 12 (32.4%) were obtained from sputum, and the other 25 (67.6%) were recovered from throat swabs. On the basis of the characteristics of resistant genes, 16 (43.2%) were β -lactamase-negative ABPC-susceptible (BLNAS) strains, 10 (27.0%) were TEM-1-type β -lactamase-positive ampicillin-resistant (BLPAR) strains, and 11 (29.8%) were Low-BLNAR. The BLNAR strain was not detected in this study (Table 1). A total of 3 different serotypes were

verified in 7 (18.9%) encapsulated *H. influenzae* strains. Of these, 2 were serotype b (Hib), 3 were serotype c, and 2 were serotype d. All the Hib strains and 2 serotype c strains were BLPAR. The other encapsulated isolates were BLNAS strains. The remaining 30 (81.1%) were verified as nontypeable strains (NTHi), of which 11 were Low-BLNAR, and 6 were BLPAR strains (Table 1).

Antimicrobial susceptibility test

The respective MIC₅₀ (MIC₉₀) values (μ g/ml) against BLNAS, BLPAR, and Low-BLNAR strains were 0.5 (0.5), 1 (2), and 0.5 (1) for ABPC/SBT; 0.015 (0.03), 0.015 (0.03), and 0.03 (0.06) for CTX; 2 (4), 2 (4), and 8 (32) for CCL; 1 (2), 0.5 (1), and 1 (2) for AZM; 0.03 (0.12), 0.015 (0.12), and 0.015 (0.03) for LVFX; and 0.5 (1), 0.25 (1), and 1 (4) for IPM (Table 2). All the isolates were susceptible to CTX, AZM, LVFX, and IPM, and there were minor differences among the activity of each of these antibiotics against BLNAS, BLPAR, and Low-BLNAR strains. One BLPAR strain was resistant to ABPC/SBT, and 4 strains were resistant to CCL, all of which were Low-BLNAR strains.

Interpretation of PFGE

Molecular typing by PFGE revealed 23 independent patterns. Only 2 PFGE patterns were detected among BLPAR strains. In this group, 8 strains were pattern A; of these, 6 were nontypeable and the other 2 were serotypes b and c. The other 2 pattern B strains were serotypes b and c (Fig. 1). In the Low-BLNAR group, 4 strains were pattern A, and the other 7 strains had different PFGE patterns (C–I) (Fig. 2). Of the 14 patterns (J–W) detected in the BLNAS group, only 1 was verified as pattern A, and this was nontypeable. Additionally, 2 NTHi strains were pattern J (Fig. 3). A total of 13 (35.1%) strains of, predominantly, pattern A were detected in all groups, of which 2 were encapsulated strains (Hib: 1, serotype c: 1) and 11 were NTHi strains.

Table 1 Characteristics of strains and distribution of serotypes

Strain	Serotypes (%)				Sputum	Throat swab (%)
	b	c	d	Nontypeable		
BLNAS	0	1	2	13	5	11
BLPAR (TEM-1)	2	2	0	6	3	7
Low-BLNAR	0	0	0	11	4	7
BLNAR	0	0	0	0	0	0
Total	2 (5.4)	3 (8.1)	2 (5.4)	30 (81.1)	12 (32.4)	25 (67.6)


BLNAS β -lactamase-nonproducing ampicillin-susceptible *H. influenzae*, BLPAR β -lactamase-producing ampicillin-resistant *H. influenzae*, Low-BLNAR low β -lactamase-nonproducing ampicillin-resistant *H. influenzae*, BLNAR β -lactamase-nonproducing ampicillin-resistant *H. influenzae*

Table 2 Susceptibility of strains to selected antibiotics

Strain	MIC ₅₀ (MIC ₉₀) / (range) (µg/ml)					
	ABPC/SBT	CTX	CCL	AZM	LVFX	IPM
BLNAS	0.5 (0.5) / (0.12–2)	0.015 (0.03) / (0.008–0.06)	2 (4) / (0.03–16)	1 (2) / (0.25–4)	0.03 (0.12) / (0.008–1)	0.5 (1) / (0.06–4)
BLPAR (TEM-1)	1 (2) / (0.25–4)	0.015 (0.03) / (0.008–0.06)	2 (4) / (2–4)	0.5 (1) / (0.12–4)	0.015 (0.12) / (0.008–0.25)	0.25 (1) / (0.12–1)
Low-BLNAR	0.5 (1) / (0.5–2)	0.03 (0.06) / (0.008–0.06)	8 (32) / (2–64)	1 (2) / (0.25–2)	0.015 (0.03) / (0.008–0.06)	1 (4) / (0.25–4)
Total	0.5 (2) / (0.12–4)	0.015 (0.03) / (0.008–0.06)	2 (16) / (0.03–64)	1 (2) / (0.12–4)	0.015 (0.12) / (0.008–1)	0.5 (4) / (0.06–4)

BLNAS β-lactamase-nonproducing ampicillin-susceptible *H. influenzae*, BLPAR β-lactamase-producing ampicillin-resistant *H. influenzae*, Low-BLNAR Low β-lactamase-nonproducing ampicillin-resistant *H. influenzae*; ABPC/SBT Ampicillin/sulbactam, CTX Cefotaxime, CCL Cefaclor, AZM Azithromycin, LVFX Levofloxacin, IPM Imipenem

Fig. 1 PFGE results for BLPAR (TEM-1) strains. DNA fragments were digested by *Sma* I restriction endonuclease; lane M contains a molecular size marker. N nontypeable, b serotype b, c serotype c



Discussion

H. influenzae is an important causative pathogen, and surveillance of antimicrobial-resistant strains is of great concern. Reportedly, up to 30% of isolates have been regarded as β-lactamase-positive strains [23]. TEM-1 enzyme has been reported to be responsible in 90–95% of isolates, and ROB-1 enzyme in 5–10% [24, 25]. In Asian countries, *H. influenzae* is isolated from approximately 15.1% of CAP patients [26]. Farrell et al. [10] reported

infrequent isolation of β-lactamase-positive *H. influenzae* strains—6.4, 19.9, and 8.0% in China, Hong Kong, and Japan compared with 67.9 and 52.6% in Taiwan and South Korea, respectively. Recently, Wang et al. [27] reported that BLPAR accounted for 14.3% of all strains isolated from pediatric outpatients in Beijing. In our study, 27% of isolates were classified as BLPAR strains, and all these were TEM-1 type. This result suggested the frequency of isolation of BLPAR might be increasing in urban areas of China. The prevalence of BLNAR strains was 9.3% in

Fig. 2 PFGE results for Low-BLNAR strains. DNA fragments were digested by *Sma* I restriction endonuclease; lane *M* contains a molecular size marker. *N* nontypeable





Fig. 3 PFGE results for BLNAS strains. DNA fragments were digested by *Sma* I restriction endonuclease; lane *M* contains a molecular size marker. *N* nontypeable, *c* serotype c, *d* serotype d



Spain between 1998 and 1999, 1.3% in France in 1999, and 2.4% in the USA between 2002 and 2003 [7, 28, 29]. Recently, Blasi et al. [30] reported that 5.2% of isolates were BLNAR strains worldwide; of these 97.5% were collected from Japan, but no such isolates were collected from China. In our study, 11 isolates were classified as

Low-BLNAR, but no BLNAR strain was detected, which is consistent with the results of previous studies [15, 16, 27]. BLNAR strains are regarded as resistant to other β -lactam agents and cephalosporins. The characteristics of the antimicrobial resistance of these strains remain of great concern in clinical prescription. Although the prevalence of

BLNAR is still rare in China, monitoring on BLNAR seems necessary to develop more practicable chemotherapy guidelines.

β -Lactam antibiotics and new quinolones are usually prescribed as empiric antibiotic therapy for respiratory tract infections in China. For those suspected of having *Mycoplasma* or *Chlamydia* infections, macrolides such as erythromycin or azithromycin are recommended, and, for severe cases, intravenous penicillin, ampicillin, cefturoxime, or cefotaxime are suggested [31, 32]. It is well known that β -lactam/ β -lactamase inhibitor combinations are usually highly active against *H. influenzae*. However, it should be noted that in this study we found one BLPAR strain with resistance to ABPC/SBT. The mechanism is currently unknown and we are working on it. It is also noteworthy that for the 2 cephalosporins tested, 4 strains (10.8%), all of which were Low-BLNAR strains, were completely resistant to CCL, and that CTX, a third-generation cephem, was much more active than CCL. Reportedly, 3% of strains were resistant to CCL in Shanghai and Beijing, and 1% in Guangzhou in 2002, and 4.2% in Beijing in 2004 [15, 27]. Compared with these results, the greater number of resistant isolates suggested reduced activity of CCL, and prescription of CCL should be recommended only for susceptible isolates according to MIC. Macrolides have also been widely used in China, and resistance to macrolides, especially of *Streptococcus pneumoniae*, has already been reported in China [33]. Recent studies have, however, reported high activity of AZM against *H. influenzae* [15, 16]. In this study, all the strains were susceptible to AZM, which is consistent with previous results. CTX, LVFX, and IPM were also highly active against all the strains. However, ABPC/SBT and CCL-resistant strains were found. These results indicate that more attention should be paid to the abuse of antibiotics in China.

PFGE is well known as one of the most sensitive fingerprint methods. In this study, BLPAR strains seemed to be concentrated in PFGE pattern A, and 4 Low-BLNAR strains (36.4%) were also pattern A; however, BLNAR strains had a variety of genetic patterns. These results suggested that ampicillin-resistant strains might be much more closely related genetically than are ampicillin-sensitive strains. Two BLPAR strains isolated from different hospitals were verified as Hib and were susceptible to all the antibiotics tested in this study except ampicillin. One Hib strain was PFGE pattern A, and the other was pattern B. These results provided evidence that at least 2 types of Hib strains were spreading horizontally in Shanghai, China. Compared with other developing Asian countries, in children aged less than 5 years the unadjusted incidence of Hib meningitis was low, estimated to be 0.98 per 100,000 child-years in China [34]. The Hib conjugate

vaccine seems to be effective not only in the prevention of invasive infections but also for reduction of nasopharyngeal carriage in young children and the incidence of respiratory tract infections such as bronchitis, etc.

This was the first clinical prospective study of the distribution of *H. influenzae* in community hospitals in a metropolitan city in China. It was also a pilot study to track the continual evolution of antimicrobial resistance of *H. influenzae* and of genetic determinants. Although this study had many limitations, for example small sample size and limited study period, it should be considered as one part of an essential approach to interrupt the spiral of antimicrobial resistance of *H. influenzae*.

In conclusion, these results demonstrated that BLPAR and Low-BLNAR strains with different genetics are increasing in urban areas of China. Although current empirical chemotherapy for CARTI patients seems to be effective, more surveillance should be implemented to improve appropriate treatments.

Acknowledgments We thank all the health care workers of the 11 community hospitals who participated in this study for their cooperation in collecting clinical specimens. This study was financially supported by a Cooperative Research Grant of NEKKEN 2010 and a Grant of Touka Kyoiku Bunka Koryu Zaidan 2009–2010.

Conflict of interest We declare that none of the authors has financial arrangements with any company whose product is mentioned prominently in this manuscript nor with any company making a competing product.

References

1. Murphy TF, Apicella MA. Nontypeable *Haemophilus influenzae*: a review of clinical aspects, surface antigens, and the human immune response to infection. *Rev Infect Dis*. 1987;9:1–15.
2. Cappelletty D. Microbiology of bacterial respiratory infections. *Pediatr Infect Dis J*. 1998;17:55–61.
3. Cripps AW, Kyd J. Bacterial otitis media: current vaccine development strategies. *Immunol Cell Biol*. 2003;81:46–51.
4. Saito M, Okada K, Takemori K, Yoshida SI. Clonal spread of an invasive strain of *Haemophilus influenzae* type b among nursery contacts accompanied by a high carriage rate of non-disease-associated strains. *J Med Microbiol*. 2000;49:845–7.
5. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens—findings of the Alexander Project 1992–1996. *J Chemother*. 1999;11:5–21.
6. Markowitz SM. Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of *Haemophilus influenzae*. *Antimicrob Agents Chemother*. 1980;17:80–3.
7. Heilmann KP, Rice CL, Miller AL, Miller NJ, Beekmann SE, Pfaller MA, et al. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of *Haemophilus influenzae* in the United States. *Antimicrob Agents Chemother*. 2005;49:2561–4.
8. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified

- in a 2005–2006 U.S. Faropenem surveillance study. *Antimicrob Agents Chemother.* 2007;51:4382–9.
9. Morrissey I, Maher K, Williams L, Shackcloth J, Felmingham D, Reynolds R. Non-susceptibility trends among *Haemophilus influenzae* and *Moraxella catarrhalis* from community-acquired respiratory tract infections in the UK and Ireland, 1999–2007. *J Antimicrob Chemother.* 2008;62:97–103.
 10. Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D. Global distribution of TEM-1 and ROB-1 beta-lactamases in *Haemophilus influenzae*. *J Antimicrob Chemother.* 2005;56:773–6.
 11. Suzuki K, Nishimura T, Baba S. Current status of bacterial resistance in the otolaryngology field: results from the Second Nationwide Survey in Japan. *J Infect Chemother.* 2003;9:46–52.
 12. Niki Y, Hanaki H, Yagisawa M, Kohno S, Aoki N, Watanabe A, et al. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility. *J Infect Chemother.* 2008;14:279–90.
 13. Liu YN, Chen MJ, Zhao TM, Wang H, Wang R, Liu QF, et al. A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China. *Zhonghua Jie He He Hu Xi Za Zhi.* 2006;29:3–8.
 14. Sun HL, Yang QW, Xu YC, Wang H, Xie XL, Chen MJ, et al. Resistance study of community respiratory pathogens isolated in China from 2005 to 2007. *Zhonghua Yi Xue Za Zhi.* 2009;89:2983–7.
 15. Shen XZ, Lu Q, Deng L, Yu SJ, Zhang H, Deng QL, et al. Surveillance of antimicrobial susceptibility of *Haemophilus influenzae* isolates from children in Beijing, Shanghai, and Guangzhou 2000–2002. *Zhonghua Yi Xue Za Zhi.* 2004;84:1335–9.
 16. Hu YY, Yu SJ, Liu G, Gao W, Yang YH. Antimicrobial susceptibility of *Haemophilus influenzae* among children in Beijing, China, 1999–2000. *Acta Paediatr.* 2002;91:136–40.
 17. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard—seventh edition M7–A7, vol. 26. Wayne: Clinical and Laboratory Standards Institute; 2006.
 18. Hasegawa K, Chiba N, Kobayashi R, Murayama SY, Iwata S, Sunakawa K, et al. Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant *Haemophilus influenzae* type b in patients with meningitis. *Antimicrob Agents Chemother.* 2004;48:1509–14.
 19. Gotoh K, Qin L, Watanabe K, Anh DD, Huong Ple T, Anh NT, et al. Prevalence of *Haemophilus influenzae* with resistant genes isolated from young children with acute lower respiratory tract infections in Nha Trang, Vietnam. *J Infect Chemother.* 2008;14:349–53.
 20. Yano H, Suetake M, Kuga A, Irinoda K, Okamoto R, Kobayashi T, et al. Pulsed-field gel electrophoresis analysis of nasopharyngeal flora in children attending a day care center. *J Clin Microbiol.* 2000;38:625–9.
 21. Qin L, Watanabe H, Asoh N, Watanabe K, Oishi K, Mizota T, et al. Short report: antimicrobial susceptibility and genetic characteristics of *Haemophilus influenzae* isolated from patients with respiratory tract infections between 1987 and 2000, including beta-lactamase-negative ampicillin-resistant strains. *Epidemiol Infect.* 2007;135:665–8.
 22. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol.* 1995;33:2233–9.
 23. Felmingham D, Gruneberg RN. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. *J Antimicrob Chemother.* 2000;45:191–203.
 24. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Brunton J, McGeer A, et al. Determination of antimicrobial susceptibilities of Canadian isolates of *Haemophilus influenzae* and characterization of their beta-lactamases. Canadian *Haemophilus* Study Group. *Antimicrob Agents Chemother.* 1994;38:1678–80.
 25. Karlowsky JA, Verma G, Zhanel GG, Hoban DJ. Presence of ROB-1 beta-lactamase correlates with cefaclor resistance among recent isolates of *Haemophilus influenzae*. *J Antimicrob Chemother.* 2000;45:871–5.
 26. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. *Int J Antimicrob Agents.* 2008;31:107–14.
 27. Wang A, Yu S, Yao K, Zhang W, Yuan L, Wang Y, et al. Antimicrobial susceptibility of *Haemophilus influenzae* strains and antibiotics usage patterns in pediatric outpatients: results from a children's hospital in China (2000–2004). *Pediatr Pulmonol.* 2008;43:457–62.
 28. Dabernat H, Plisson-Saune MA, Delmas C, Seguy M, Faucon G, Pelissier R, et al. *Haemophilus influenzae* carriage in children attending French day care centers: a molecular epidemiological study. *J Clin Microbiol.* 2003;41:1664–72.
 29. Marco F, Garcia-de-Lomas J, Garcia-Rey C, Bouza E, Aguilar L, Fernandez-Mazarrasa C. Antimicrobial susceptibilities of 1,730 *Haemophilus influenzae* respiratory tract isolates in Spain in 1998–1999. *Antimicrob Agents Chemother.* 2001;45:3226–8.
 30. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003–2004). *Diagn Microbiol Infect Dis.* 2009;63:302–8.
 31. Chinese society of respiratory diseases. She qu huo de xing fei yan zhen duan he zhi liao zhi nan (Guideline for diagnosis and treatment of community acquired pneumonia). *Chin J Tuberc Respir Dis.* 1999;22:199–201 (article in Chinese).
 32. Xu ZJ, Ding K, Huang H, Sun TY, Ke HX, Tong ZH, et al. Questionnaire survey of guideline implementation for community acquired pneumonia with retrospective analysis the empiric treatment in 490 patients. *Chin J Tuberc Respir Dis.* 2007;30:442–6 (article in Chinese).
 33. Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. *BMC Infect Dis.* 2009;9:1–9.
 34. Shetty S, Cohen AL, Edmond K, Ojo L, Loo J, O'Loughlin R, et al. A systematic review and critical evaluation of invasive *Haemophilus influenzae* type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. *Pediatr Infect Dis J.* 2010;29:653–61.

成人予防接種のガイドンス

日本内科学会成人予防接種検討ワーキンググループ編著

二木 芳人 大石 和徳 川上 和義 谷口 清州

渡辺 彰 渡邊 浩

成人予防接種のガイドンス

日本内科学会成人予防接種検討ワーキンググループ編著

二木 芳人¹⁾ 大石 和徳²⁾ 川上 和義³⁾ 谷口 清州⁴⁾
渡辺 彰⁵⁾ 渡邊 浩⁶⁾

[日内会誌 101 : 3585~3597, 2012]

Keywords 肺炎球菌ワクチン, インフルエンザワクチン, 麻疹・風疹ワクチン, 帯状疱疹ワクチン, 高齢者

はじめに

感染症は今日、複雑・難治化の傾向を認め、その背景には医療の高度化や高齢人口の増大、さらには各種の新興・再興感染症の発生、薬剤耐性病原菌の増加などがあると思われまふ。この様な感染症は時に治療は困難を極め、予後不良を招くことも高齢者や基礎疾患を有する患者では稀ならずあります。従って、可能な限りその発症や重症化を予防することが望まれます。ワクチンなどの予防接種はその一つの手段として広く応用されているものですが、わが国では欧米に比べその理解と普及に若干の遅れが指摘されてきました。しかし2009年に我々は新型インフルエンザのパンデミックを経験し、その際

に予防接種の重要性にようやく気付かされたと言つても過言ではないでしょう。

小児科領域では昨今相次いで新しいワクチンも導入され、日本小児科学会では学会の推奨する小児の予防接種のスケジュールなども公表されています。今回、日本内科学会では、現在我が国で接種可能な成人の予防接種について現在の状況をまとめ、有効性に関するエビデンスが認められ、広く一般にもコンセンサスの得られているものを一つの指針として本ガイドンスを公表いたします。

1. 一般に推奨される予防接種

1) 肺炎球菌ワクチン

1) 昭和大学臨床感染症学講座；ワーキンググループ責任者、2) 国立感染症研究所感染症情報センター、3) 東北大学大学院医学系研究科保健学専攻、4) 三重大学小児科、5) 東北大学加齢医学研究所抗感染症薬開発研究部門、6) 久留米大学医学部感染医学講座臨床感染医学部門

Guidance for vaccination in adult.

Yoshihito Niki¹⁾, Kazunori Oishi²⁾, Kazuyoshi Kawakami³⁾, Kiyosu Taniguchi⁴⁾, Akira Watanabe⁵⁾ and Hiroshi Watanabe⁶⁾ :

¹⁾Department of Clinical Infectious Diseases, Showa University School of Medicine, Japan, ²⁾Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan, ³⁾Department of Medical Microbiology, Mycology and Immunology, Tohoku University Graduate School of Medicine, Japan, ⁴⁾Department of Pediatrics, Mie University Graduate School of Medicine, Japan, ⁵⁾Research Division for Development of Anti-Infective Agents, Institute of Development, Aging and Cancer, Tohoku University, Japan and ⁶⁾Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, Japan.